Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT was delisted on the 31st of December, 2020.
2 hedge funds and large institutions have $1.27M invested in Bristol-Myers Squibb Company Contingent Value Rights in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JCI
Jet Capital Investors
New York
|
+$1.27M |
Top Sellers
BMY.RT Hedge Fund Activity: Q3 2023 in Review
2 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q3 2023, worth a combined $1.27M.
Buyers outnumbered sellers: 1 fund opened new BMY.RT positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Jet Capital Investors, opening a new position worth an estimated $1.27M.
- 2 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q3 2023, up from 1 in Q2 2023.
- Funds reported $1.27M of Bristol-Myers Squibb Company Contingent Value Rights stock for Q3 2023.
- 1 fund opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q3 2023 and 0 closed out, a net change of +1 holder.
- The largest Bristol-Myers Squibb Company Contingent Value Rights buyer in Q3 2023 was Jet Capital Investors, an estimated $1.27M added.
Based on aggregated 13F filings for Q3 2023.